The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab

<table>Change in central retinal thickness (<i>μ</i>m) from baseline and to the 3-, 6-, 12-, and 24-month follow-up in the AMD group and AMD/ERM group. (Respective intravitreal injections administered at months 0, 1, and 2 and then as per treatment protocol.)</table>

The Scientific World Journal

fig2

Figure 2

Figure 2: The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab 